Menu
/REGISTER
Montecito
Tolman Wiker
Pac Premier
Fielding
Farmers merchants
Loading...
You are here:  Home  >  Biotech  >  Current Article

Amgen fends off biosimilar for arthritis drug Enbrel

By   /   Friday, August 16th, 2019  /   Comments Off on Amgen fends off biosimilar for arthritis drug Enbrel

    Print       Email
In a court victory with broad implications for the biotech industry, Amgen secured protection through 2028 for its top-selling arthritis drug Enbrel, furthering its defense against encroachment by biosimilar competitors. The ruling Aug. 8 in a New Jersey District Court permanently blocked sales of a biosimilar developed by Sandoz, a German division of Swiss multinational…

Subscribe

    This article is only available to Business Times subscribers
  • Subscribers: LOG IN or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.
    Print       Email

You might also like...

CLU adds cybersecurity to master’s degree in IT program

Read More →